ReviewCurrent hypertension reports2001
Angiotensin, inflammation, hypertension, and cardiovascular disease.
Review in Current hypertension reports, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 54 citations in OpenAlex.
- Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.Journal of the American Society of Nephrology : JASN · 2012Trial
- Chronic β-Blockade and Systemic Homeostasis: Molecular Integration of Cardiorenal and Immune Pathways, a Narrative Review.Biomolecules · 2025Review
- Direct simulation of hypertensive stress on endothelial cells: a streamlined model of in-vitro-hypertension.Frontiers in physiology · 2025Article
- A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan.Frontiers in cardiovascular medicine · 2022Article
- Ascorbic Acid: A New Player of Epigenetic Regulation in LPS-Oxidative medicine and cellular longevity · 2021Article
- Insulin Resistance the Hinge Between Hypertension and Type 2 Diabetes.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020Review
- Mechanisms of isolevuglandin-protein adduct formation in inflammation and hypertension.Prostaglandins & other lipid mediators · 2018Review
- Angiotensin II-induced Hypertension is Reduced by Deficiency of P-selectin Glycoprotein Ligand-1.Scientific reports · 2018Article
- Role and therapeutic potential of G-protein coupled receptors in breast cancer progression and metastases.European journal of pharmacology · 2015Review
- Positioning of inflammatory biomarkers in the heart failure landscape.Journal of cardiovascular translational research · 2013Review
- Upregulation of junctional adhesion molecule-A is a putative prognostic marker of hypertension.Cardiovascular research · 2012Article
- The effect of an Angiotensin receptor blocker on arterial stiffness in type 2 diabetes mellitus patients with hypertension.Diabetes & metabolism journal · 2011Article
- Pentosan polysulfate treatment preserves renal autoregulation in ANG II-infused hypertensive rats via normalization of P2X1 receptor activation.American journal of physiology. Renal physiology · 2010Article
- Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness.Integrated blood pressure control · 2010Article
- Inflammation in lone atrial fibrillation.Clinical cardiology · 2009Article
- Mast cell renin and a local renin-angiotensin system in the airway: role in bronchoconstriction.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- LDL cholesterol angiotensin II interactions in atherosclerosis.Journal of molecular medicine (Berlin, Germany) · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We are used to thinking of angiotensin (Ang) II as a regulatory hormone that stimulates constriction of vascular smooth muscle cells, aldosterone release from the adrenal gland, and sodium reabsorption in the renal tubule. We have also become accustomed to understanding that Ang II may be formed and may act locally as a chemokine that induces tyrosine phosphorylation, cell growth, hypertrophy, and differentiation. Viewing Ang II as an inflammatory molecule is stranger still. Nevertheless, recent evidence shows that Ang II is important in stimulating the production of reactive oxygen species and the activation of ancient inflammatory mechanisms. The nuclear factor kappaB (NF-kappaB) is pivotal to these processes. Activation of NF-kappaB stimulates the expression of a gene menagerie that is important to chemoattraction, expression of surface adhesion molecules, coagulation, and inflammation. In addition, Ang II has been shown to regulate cellular immune responses. It stimulates the proliferation of lymphocytes and contributes to their activation via calcineurin-related pathways. Knowledge of these mechanisms may provide additional therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.